# US 2024/0199576 A1 · Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199576 A1
- Document ID: US20240199576A1
- Status: Published application
- Kind: A1
- Application number: 18/551,699
- Filed: 2022-03-24
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: Novartis AG; Cadent Therapeutics, Inc.
- Applicants: Novartis AG; Cadent Therapeutics, Inc.
- Inventors: Mark Patrick HEALY; Yue PAN; Kate Yaping WANG
- Web page: https://patentgrep.com/patent/US20240199576A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- C07D 209/52: condensed with a ring other than six-membered
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides a combination of pharmacologically active agents and a pharmaceutical composition.

## Claims

### Claim 1

A compound of Formula I (II:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a C3-8cycloalkyl, C3-7heterocyclyl, phenyl, naphthyl, or heteroaryl, each of which is optionally substituted with one or more R5;
R2 is OH, CN, halogen, OR6, SH, SR6, C1-6alkyl, haloC1-6alkyl, NH2, NHR6, hydroxyC1-6alkyl, N(R6)(R6′), NHS(O)2R6, or NHCOR6;
R3 is H, O, or OH;
R4 is H or OH;
R5 is halogen, OH, C1-6alkyl, haloC1-6alkyl, OR6, CN, NH2, NHR6, N(R6)(R6′), SH, SR6, SOR6, SO2R6, SO2NHR6, SO2N(R6)(R6′), CONH2, CONHR6, or CON(R6)(R6′);
each R6 and R6′ is independently selected from the group consisting of H, O—C1-6alkyl, C1-6alkyl, and haloC1-6alkyl;
B is N or CRx;
each Rx is independently H, C1-3alkyl, or halogen; and
each n is independently 0, 1, or 2.

### Claim 2 (depends on 1)

A compound according to claim 1 of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
R2 is OH, CN, halogen, OR6, SH, SR6, C1-6 alkyl, haloC1-6alkyl, NH2, NHR6, hydroxyC1-6 alkyl, N(R6)(R6′), NHS(O)2R6, or NHCOR6;
R3 is H, O, or OH;
R4 is H or OH;
R5 is halogen, OH, C1-6 alkyl, haloC1-6alkyl, OR6, CN, NH2, NHR6, N(R6)(R6′), SH, SR6, SOR6, SO2R6, SO2NHR6, SO2N(R6)(R6′), CONH2, CONHR6, or CON(R6)(R6′);
each R6 and R6′ is independently selected from the group consisting of H, O—C1-6 alkyl, C1-6 alkyl, and haloC1-6alkyl;
B is N or CRx;
each Rx is independently H, C1-3 alkyl, or halogen; and
each n is independently 0, 1, or 2.

### Claim 3 (depends on 1)

A compound according to claim 1 of Formula (III);
or a pharmaceutically acceptable salt thereof, wherein:
R2 is halogen;
R3 is H or OH;
R4 is H or OH;
R5 is halogen;
each A is independently N or CH, provided that when one A is N the other is CH;
B is N or CH; and
each n is independently 0, 1, or 2.

### Claim 4 (depends on 3)

The compound according to claim 3 of Formula (IIIa):
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 3)

The compound according to claim 3 of Formula (IIIb):
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 3)

The compound according to claim 3 of Formula (IIIc):
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 3)

The compound according to claim 3 of Formula (IIId):
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 3)

The compound according to claim 3 of Formula (IIIe):
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 3)

The compound according to claim 3 of Formula (IIIf):
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R5 is F.

### Claim 11 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R2 is F or Cl.

### Claim 12 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R3 is H.

### Claim 13 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R3 is OH.

### Claim 14 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R4 is H.

### Claim 15 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R4 is OH.

### Claim 16 (depends on 1)

The compound of Formula (I) according to claim 1, wherein B is N.

### Claim 17 (depends on 1)

The compound of Formula (I) according to claim 1, wherein B is CH.

### Claim 18 (depends on 1)

The compound of Formula (I) according to claim 1, wherein A is N, provided that when one A is N the other A is CH.

### Claim 19 (depends on 1)

The compound of Formula (I) according to claim 1, wherein A is CH.

### Claim 20 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R2 is halogen, C1-6alkyl, haloC1-6alkyl, or hydroxyC1-6alkyl.

### Claim 21 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R2 is halogen, C1-6alkyl, or haloC1-6alkyl.

### Claim 22 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R5 is halogen, OH, C1-6alkyl, OR6, CN, SH, or SR6.

### Claim 23 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R5 is halogen, OH, C1-6alkyl, or OR6.

### Claim 24 (depends on 1)

The compound of Formula (I) according to claim 1, wherein R5 is halogen, OH, or C1-6alkyl.

### Claim 25

A compound which is:
(3aS,5S,6aR)-5-(2-fluorophenoxy)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-(2-fluorophenoxy)-2-((R)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-(2-fluorophenoxy)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-(2-fluorophenoxy)-2-((R)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,4S,5S,6aR)-5-(2-fluorophenoxy)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-5-(2-fluorophenoxy)-2-((R)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-5-(2-fluorophenoxy)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-5-(2-fluorophenoxy)-2-((R)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((S)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((R)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((S)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((R)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((S)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((R)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((S)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((R)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,4S,5S,6aR)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aR,4R,5R,6aS)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrole-3a,4(1H)-diol;
(3aS,5S,6aR)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-hydroxy-2-(5-hydroxypyridin-2-yl)ethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((S)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((R)-2-(6-fluoro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((S)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-(6-chloro-5-hydroxypyridin-2-yl)-2-hydroxyethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((R)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-((S)-2-(3,5-difluoro-4-hydroxyphenyl)-2-hydroxyethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-(2,4-difluorophenoxy)-2-((R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-(2,4-difluorophenoxy)-2-((S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-(2,4-difluorophenoxy)-2-((R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-(2,4-difluorophenoxy)-2-((S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-(2-fluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-(2,4-difluorophenoxy)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-2-(3,5-difluoro-4-hydroxyphenethyl)-5-phenoxyhexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-((3-fluoropyridin-2-yl)oxy)-2-(4-hydroxyphenethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-((3-fluoropyridin-2-yl)oxy)-2-(4-hydroxyphenethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-((2-fluoropyridin-3-yl)oxy)-2-(4-hydroxyphenethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-((2-fluoropyridin-3-yl)oxy)-2-(4-hydroxyphenethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-(2,4-difluorophenoxy)-2-(2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aR,5R,6aS)-5-(2,4-difluorophenoxy)-2-(2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol;
(3aS,5S,6aR)-5-((2-fluoropyridin-3-yl)oxy)-2-(2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol; and
(3aR,5R,6aS)-5-((2-fluoropyridin-3-yl)oxy)-2-(2-(5-hydroxypyridin-2-yl)ethyl)hexahydrocyclopenta[c]pyrrol-3a(1H)-ol, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

A method for the treatment of Parkinson's disease, Huntington's disease, Rett syndrome, amyotrophic lateral sclerosis, multiple sclerosis, seizure disorders, autism, autism spectrum disorders, Fragile X syndrome, tuberous sclerosis, Down's syndrome, pain, migraine, tinnitus, bipolar disorder, obsessive-compulsive disorder, anxiety disorder, post-traumatic stress disorder (PTSD), cocaine use disorder, major depressive disorder, refractory or treatment resistant depression, or suicidality comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof to a patient in need of treatment thereof.

### Claim 28 (depends on 27)

The method of claim 27, comprising administering a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof.
